ClinicalTrials.gg
RecruitingNCT06152627RTSS-VoiceUpdated May 26, 2026

Voice Therapy Per the Rehabilitation Treatment Specification System

An interventional study of Standard of care voice therapy with novice clinician RTSS-Voice documentation and Standard of care voice therapy with expert clinician RTSS-Voice documentation in Muscle Tension Dysphonia, sponsored by Massachusetts General Hospital. Recruiting at 5 sites in United States. Open to participants aged 14 Years and older. Per ClinicalTrials.gov, last updated 2026-05-26.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
600
Allocation
Non-randomized
Ages
14 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 71 studies in Dysphonia with a site in United States — 20 open to participants now, 21 under way, 1 of them phase 3. Dysphonia · United States.

Planned enrollment
2nd of 53
600 · median 32
Started
2026
with 5 others
No phase
31 of 71
12 open now
Primary completion
2027-06
later than 6 of 20 live
Registered
61st of 71
by date
Lead sponsor
2 of 71
Massachusetts General Hospital

Among the 71 studies in Dysphonia with a site in United States, this one is the 2nd largest by planned enrollment of the 53 interventional ones that give a count, is one of 6 that started in 2026, is one of 31 with no phase, reaches primary completion later than 6 of the 20 other live ones, and was the 61st registered.

Dysphonia

132 studies on the registry are indexed under Dysphonia; 38 are open to participants now.

Browse Dysphonia studies →

Open to participants now

20 of the 71 studies in Dysphonia with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 25 Dysphonia studies recruiting now, 8 (32%) set no upper age limit and 9 (36%) stop at 75 or younger; 7 take children under 18; 14 take healthy volunteers.

This study: 14 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Dysphonia with a site in United States, or all of them as a file.
02

Study summary

The goal of this study is to evaluate if using evidence-based, standard ingredient and target codes from the Rehabilitation Treatment Specification System - Voice Therapy (RTSS-Voice) in standard of care voice therapy documentation can improve outcomes for patients with muscle tension dysphonia (MTD). The main question it aims to answer is: Since the RTSS-Voice will help clinicians think about their treatment more specifically and in relation to nine evidence-based therapies, will its adoption be associated with improved outcomes? Clinicians across five voice centers will be asked to use the RTSS-Voice to document their voice therapy sessions for patients with MTD. Researchers will compare changes in outcomes between two groups of patients: those treated during the clinician's first year using the RTSS-Voice versus those treated during the clinician's second year using the RTSS-Voice.

Read the detailed description

The purpose of this study is to evaluate if using evidence-based, standard ingredient and target codes from the Rehabilitation Treatment Specification System - Voice Therapy (RTSS-Voice) in standard of care voice therapy documentation can improve outcomes for patients with muscle tension dysphonia (MTD). RTSS-Voice adoption is likely to be associated with improved outcomes because it requires clinicians to think about their therapy in relation to nine evidence-based therapies (i.e., increased evidence-based practice) and more carefully consider the specific changes in targets directly related to specific clinical actions, i.e., improved clinical reasoning. Sixty patents will be enrolled per year (at minimum) from each of the five participating voice centers, i.e., 300 patients in Years 1 and 2 (total patients = 600). For each patient, outcomes will be collected before and after therapy including patient-reported vocal functioning, clinician-reported voice quality, an objective measure associated with overall voice quality (Cepstral Peak Prominence/CPP), and total number of sessions. Each voice center uses different patient-reported and clinician-reported measures. Thus, linear regression models will examine changes in outcomes during Year 1 versus Year 2 for each individual site. The different patient- and clinician-reported measures have been found to be highly correlated. Therefore, individual sites will also be pooled together in a mini meta-analysis. Standardized effect sizes (Cohen's d) will be calculated for each site, representing the effect of RTSS-Voice adoption. Using a fixed effects model, an average effect size across sites will be calculated, weighted by sample size. The average effect size across sites will then represent the overall effect of the implementation on vocal functioning, voice quality, CPP, and number of sessions. Power: The investigators anticipate a minimum of 60 patients per site, (total of 300 patients per year). For site-specific analyses, a sample size of 60 patients for each group (Year 1 versus Year 2) is associated with 80% power to detect the smallest clinically meaningful effect size: d = .5. The effect size d = .5 was chosen because it is the smallest effect that is "visible to the naked eye" associated with rejecting the null hypothesis and supporting the alternative hypothesis in rehabilitation treatment studies and used in multiple voice studies.

03

Conditions studied

  • Muscle Tension Dysphonia

Browse trials for

Keywords

  • Muscle tension dysphonia
  • rehabilitation
  • treatment
04

Who can participate

Ages eligible
14 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of primary Muscle Tension Dysphonia (pMTD)
  • Patients with pMTD will be included regardless of subtype (e.g., functional aphonia, vocal fry, ventricular dysphonia) and they can have secondary diagnoses of reflux.

Exclusion criteria

Exclusion Criteria:

  • Patients diagnosed with pMTD will be excluded if they have secondary diagnoses related to structural, neurological, or respiratory disorders such as laryngitis, obvious vocal fold nodules, polyps, cyst, granuloma, sulci, paradoxical vocal fold motion, chronic cough, confirmed or possible upper airway paralysis/paresis, dysphagia, polypoid corditis, keratosis, presbylarynx, leukoplakia, or history of radiation to the head/neck. Patients with pMTD will be included regardless of subtype (e.g., functional aphonia, vocal fry, ventricular dysphonia) and they can have secondary diagnoses of reflux.
  • Non-English speakers. The RTSS-Voice's standard and operationalized categories are in English.
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
Single (Outcomes assessor)
Enrollment
600 participants (estimated)

Study arms

  • Experimental
    First Year of RTSS-Voice use

    These 300 patients from five Voice Centers will receive standard of care voice therapy where their treating clinicians will be trained to use the RTSS-Voice in their documentation.

    Behavioral: Standard of care voice therapy with novice clinician RTSS-Voice documentation

  • Experimental
    Second Year of RTSS-Voice use

    These 300 patients from five Voice Centers will receive standard of care voice therapy where their treating clinicians have already been trained to use the RTSS-Voice in their documentation.

    Behavioral: Standard of care voice therapy with expert clinician RTSS-Voice documentation

Interventions

  • BehavioralStandard of care voice therapy with novice clinician RTSS-Voice documentation

    Voice therapy is individually tailored to each patient and typically includes behavioral ingredients (e.g., applying pressure to the anterior neck, practice voicing in various ways, feedback on performance, provide information on the importance of therapy concepts) to modify the patient's auditory, somatosensory, vocal, musculoskeletal, respiratory, and mental functions. During this time, the treating clinicians will be trained to use the RTSS-Voice in their clinical documentation.

  • BehavioralStandard of care voice therapy with expert clinician RTSS-Voice documentation

    Voice therapy is individually tailored to each patient and typically includes behavioral ingredients (e.g., applying pressure to the anterior neck, practice voicing in various ways, feedback on performance, provide information on the importance of therapy concepts) to modify the patient's auditory, somatosensory, vocal, musculoskeletal, respiratory, and mental functions. During this time, the treating clinicians will have completed their RTSS-Voice training and using the RTSS-Voice in their clinical documentation.

06

What researchers measure

Primary outcomes

  1. Voice Health Index (VHI)

    The VHI consists of 30 Likert questions ranging from 0-4 (0 = never, 1 = almost never, 2 = sometimes, 3 = almost always, 4 = always) that estimate how the patient's vocal function effects his/her daily life. A short-form can be used (the VHI-10) that uses a subset of 10 questions from the 30 total questions. This patient-reported outcome measure will be used to evaluate if the patients perceive that therapy helped them function better in their activities of daily living.

    Time frame: pre-intervention and immediately after the intervention

  2. Voice-Related Quality of Life (V-RQOL)

    The V-RQOL consists of 10 Likert-style questions ranging from 1-5 (1 = none not a problem at all, 2 = a small amount, 3 = a moderate (medium) problem, 4 = a lot, 5 = problem is "as bad as it can be") that estimate how the subject's vocal function effects his/her daily life. This patient-reported outcome measure will be used to evaluate if the patients perceive that therapy helped them function better in their activities of daily living.

    Time frame: pre-intervention and immediately after the intervention

  3. Consensus Auditory Perceptual Evaluation of Voice (CAPE-V)

    The CAPE-V consists of 4 perceptually judged 100-mm visual analog scales (Overall dysphonia, Breathiness, Strain, Roughness). The patient's treating voice specialized speech-language pathologist will judge the audio samples. These judgements provide gold-standard, perceptual ratings of voice quality to evaluate if voice therapy is associated with improved voice quality.

    Time frame: pre-intervention and immediately after the intervention

  4. Grade Roughness Breathiness Asthenia Strain (GRBAS) Scale

    The GRBAS consists of 5 perceptually-judged scales (Grade, Roughness, Breathiness, Asthenia, Strain) on a 0-3 Likert scale (0 = normal, 1 = mild severity, 2 = moderate severity, 3 = severe). The patient's treating voice specialized speech language pathologist will judge the audio samples. These judgements provide gold-standard, perceptual ratings of voice quality to evaluate if voice therapy is associated with improved voice quality.

    Time frame: pre-intervention and immediately after the intervention

  5. Cepstral Peak Prominence (CPP)

    To calculate CPP, all voiced 50 millisecond (ms) frames will undergo two discrete Fourier transforms computed in succession with a logarithmic transformation between them. A regression line is then computed over quefrencies greater than 2 ms (corresponding to a quefrency range minimally affected by subglottal resonances). Finally, the CPP for each frame is defined as the difference, in decibels (dB), between the magnitude of the highest peak and the baseline regression level in the power cepstrum. The peak search is limited to quefrencies between 2.5 ms and 12 ms, corresponding to frequencies of 417 Hertz (Hz) and 83 Hz, respectively. The resulting CPP is an estimate of periodicity in the voice signal, which has strongly correlated to overall dysphonia in multiple previous studies. This will be used to quantitatively evaluate if voice therapy was associated with improved overall voice quality.

    Time frame: pre-intervention and immediately after the intervention

07

Study locations

5 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — We expect to share de-identified data on the 600 patients before and after therapy. Specifically, changes in patient-reported outcomes, clinician-reported outcomes, an objective measure of periodicity, and number of therapy sessions.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data collection will be finished by August 2027. Since the data is de-identified at time of data collection, we will plan to submit the data as soon as possible to a generalist repository approved by the PI's home institution and meets all National Institutes of Health Generalist Repository requirements: Harvard Dataverse. The National Institute on Deafness and Other Communication Disorders participates in multiple domain specific repositories (aphasia, fluency, multiple brain repositories, mice work, and Downs syndrome). However, there are no domain-specific repositories for voice, voice disorders, or motor control/learning data.

Access criteria: The study datasets will be collected with the following informed consent: Health/Medical/Biomedical. To maximize the appropriate sharing of scientific data and protect research participants' privacy and confidentiality, reuse of this dataset should use the following Data Use Limitations under Controlled Access that is made available by a data repository only after approval of the request by the Harvard Dataverse independent review panel process.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Jun 2027, 16 months after the start.

Of 44 non-industry interventional studies with no phase under Dysphonia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 47. This study's planned 16 months is below that.

Counting every sponsor, half of 44 studies reached it within 26 months; a quarter within 11 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2023
First posted
Nov 30, 2023
StartActual
Feb 3, 2026
Primary completionEst.
Jun 29, 2027
CompletionEst.
Jun 29, 2027
Last update
May 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06152627
Responsible party
Jarrad Van Stan (Associate Professor of Surgery and Speech-Language Pathology, Massachusetts General Hospital) — Principal investigator
First posted
Nov 30, 2023
Start date
Feb 3, 2026
Primary completion
Jun 29, 2027 (estimated)
Completion
Jun 29, 2027 (estimated)
Last update
May 26, 2026

Study contacts

Jarrad Van Stan, PhD, CCC-SLP
Contact
jvanstan@mgh.harvard.edu
617-643-8410
Jarrad Van Stan, PhD, CCC-SLP
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion